Aleksandar Skuban

Dr. Skuban brings to Brii Bio more than 25 years of global pharmaceutical R&D experience with an extensive medical, scientific and business leadership track record of achievements, including leading more than 30 studies across therapeutic areas from early stage proof of concept through positive regulatory outcomes, with a focus in central nervous system (CNS) diseases. Previously, Dr. Skuban served as SVP of Clinical Development at Better Therapeutics, where he shaped research strategy to enable rapid development of new indications for prescription digital therapeutics. Prior to that, he served as an Executive Medical Director leading clinical development within Alexion’s emerging ophthalmology therapeutic area. At Otsuka Pharmaceuticals, Dr. Skuban’s tenure included roles overseeing various clinical portfolios, notably guiding to FDA approval for Brexpiprazole (REXULTI) for major depressive disorder and schizophrenia.

Dr. Skuban also held a number of clinical development director roles at Merck and Sanofi-Aventis. He earned a M.D. from Semmelweis University of Medicine, Budapest, Hungary and attended the School of Medicine at the University of Novi Sad, Novi Sad, Yugoslavia (Serbia).